Literature DB >> 8494392

Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.

E B Bastone1, S C Li, L L Ioannides-Demos, W J Spicer, A J McLean.   

Abstract

The relative influence of peak concentration (Cmax) versus the area under the antibiotic concentration-time curve (AUC) on the bactericidal effect of gentamicin against Escherichia coli NCTC 10418 was studied. Bacteria in the lag phase were exposed to an in vitro gentamicin concentration series which mirrored the concentrations determined in patients after 80-mg intravenous bolus (1 min) and 80-mg intravenous infusion (30 min) doses. Bacterial viable cell counts and gentamicin concentrations were measured before and during antibiotic exposure. Both the Cmax and AUC were shown to be factors determining antibacterial activity; however, the Cmax was an independent determinant of effect. These findings indicate that bolus intravenous dosing with gentamicin could maximize bactericidal activity. Increased efficacy could result at any given daily antibiotic dose if delivered via bolus with long intervals (12 to 24 h) between doses if appropriate precautions to avoid toxicity are taken.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494392      PMCID: PMC187813          DOI: 10.1128/AAC.37.4.914

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Effect of penicillin dosage schedule on treatment of experimental typhoid infections in mice.

Authors:  A K MILLER; D L WILMER; W F VERWEY
Journal:  Proc Soc Exp Biol Med       Date:  1950-05

2.  Intravenous injection of gentamicin and tobramycin without impairment of hearing.

Authors:  S M Dobbs; G E Mawer
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

3.  Safety of the bolus administration of gentamicin.

Authors:  J Mendelson; J Portnoy; V Dick; M Black
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

4.  Letter: Serum levels of gentamicin after intravenous bolus injection.

Authors:  R R Bailey; K L Lynn
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

5.  Kill kinetics and regrowth pattern of bacteria exposed to antibiotic concentrations simulating those observed in vivo.

Authors:  J P Guggenbichler; E Semenitz; P König
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

6.  New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.

Authors:  S Grasso; G Meinardi; I de Carneri; V Tamassia
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

7.  Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

Authors:  A U Gerber; H P Brugger; C Feller; T Stritzko; B Stalder
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

8.  Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.

Authors:  A U Gerber; W A Craig; H P Brugger; C Feller; A P Vastola; J Brandel
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

Review 9.  Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria.

Authors:  J Klastersky; J P Thys; G Mombelli
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

10.  Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro.

Authors:  A U Gerber; P Wiprächtiger; U Stettler-Spichiger; G Lebek
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

View more
  11 in total

1.  Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.

Authors:  P J Wood; L L Ioannides-Demos; E B Bastone; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Intravenous Push Administration of Antibiotics: Literature and Considerations.

Authors:  Samantha Spencer; Heather Ipema; Patricia Hartke; Courtney Krueger; Ryan Rodriguez; Alan E Gross; Michael Gabay
Journal:  Hosp Pharm       Date:  2018-03-08

3.  A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides.

Authors:  D Czock; M Giehl; F Keller
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

4.  Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria.

Authors:  Yuma A Bijleveld; Maria E van den Heuvel; Caspar J Hodiamont; Ron A A Mathôt; Timo R de Haan
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.

Authors:  Robert T Cass; Carter D Brooks; Nancy A Havrilla; Kenneth J Tack; Marie T Borin; Don Young; Jon B Bruss
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

6.  Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047.

Authors:  C R Rayner; L L Ioannides-Demos; J A Brien; L L Liolios; W J Spicer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.

Authors:  L L Ioannides-Demos; L Liolios; P Wood; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study.

Authors:  Elisabet I Nielsen; Marie Sandström; Per Hartvig Honoré; Uwe Ewald; Lena E Friberg
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.

Authors:  A A Firsov; D Saverino; D Savarino; M Ruble; D Gilbert; B Manzano; A A Medeiros; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia.

Authors:  Yuma A Bijleveld; Timo R de Haan; Hanneke J H van der Lee; Floris Groenendaal; Peter H Dijk; Arno van Heijst; Rogier C J de Jonge; Koen P Dijkman; Henrica L M van Straaten; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Debbie H G M Nuytemans; Anton H van Kaam; Ron A A Mathot
Journal:  Br J Clin Pharmacol       Date:  2016-03-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.